Komori
StemRIM (4599) · PolicyAdvanced

Fixed compensation and stock options to promote long-term corporate value creation

First written in FY2020. 19 of 22 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.

22entries
7years
7from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY2022-Q1 – FY2022-Q3AdvancedFY2023-Q1 – FY20262020: 12021: 220212022: 320222023: 220232024: 320242025: 220252026: 92026
Same theme, other companies
Executive Compensation Policy and Design Combining Fixed and Share-Based CompensationA theme 90 companies write about · 12 as a headwind · 57 as a tailwind

The whole theme swung hardest in 2024: 8 of 45 companies on the "Worse" side.

22 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 90 companies compared. The sentences above are computed from all 90.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「At a meeting of the Board of Directors held on 9 September 2026, the Company resolved to issue stock acquisition rights as stock options to its directors and employees. The rights were issued on 10 September 2026.」

    Based on a policy centered on fixed compensation and designed to encourage the enhancement of corporate value over the medium to long term, additional issues of the 19th and 20th series of stock acquisition rights were made for directors, employees and others.
  2. FY2026-H1AdvancedAnnual report

    「Increase/decrease in total number of shares issued: 545,000 (Note) The increase resulted from the issuance of new shares as restricted stock compensation. Allottees: 2 directors and 3 audit & supervisory board members of the Company」

    As a stock compensation initiative to promote medium- to long-term growth in corporate value, 545,000 restricted shares were issued to 2 directors and 3 audit & supervisory board members. The 17th and 18th series of stock acquisition rights, for executive officers, employees, external collaborators and directors, were also issued.
  3. FY2025AdvancedAnnual report

    「At a meeting of the Board of Directors held on 10 September 2025, the Company resolved to issue stock acquisition rights as stock options to its directors, employees, dispatched employees and outside collaborators, with the aim of enhancing motivation and morale to contribute to the progress of the Company's research and development and thereby contributing to the enhancement of corporate value. The rights were issued on 11 September 2025 and 26 September 2025.」

    After the filing date, the issuance of stock acquisition rights to directors, employees and others as part of a stock incentive plan aimed at enhancing corporate value over the medium to long term was further specified.
  4. FY2025-H1AdvancedAnnual report

    「11 December 2024 (Note) 2 475,000 62,036,600 85,025 101,460 85,025 9,513,535」

    475,000 common shares were issued to 2 directors and 3 audit & supervisory board members as restricted stock compensation. The medium- to long-term stock compensation measure is making tangible progress.
  5. FY2024AdvancedAnnual report

    「The current compensation structure is based on fixed compensation, with a restricted stock compensation plan and a stock option plan introduced as long-term incentives for directors and audit & supervisory board members. The Company has not introduced performance-linked compensation that varies with short-term results.」

    The medium- to long-term incentive policy of combining fixed compensation with restricted stock and stock options was reaffirmed, and 433,000 restricted shares and other awards were issued to officers during the fiscal year.
  6. FY2024-Q3AdvancedAnnual report

    「This was mainly due to the recognition of a quarterly net loss of ¥1,519.000 million, while capital stock and capital surplus each increased by ¥202.319 million as a result of the exercise of share acquisition rights and the issuance of restricted shares as stock compensation for officers.」

    The issuance of restricted shares as stock compensation for officers was carried out, further specifying the medium- to long-term stock compensation measure.
  7. FY2024-Q2AdvancedAnnual report

    「Name: Series 15 Stock Acquisition Rights (a) Resolution date: 13 December 2023 Category and number of grantees (people): Company outside collaborator, 1 Number of stock acquisition rights (units)*: 300 (Note 1) Class, description and number of shares underlying the stock acquisition rights (shares)*: Common stock, 30,000 (Note 1)」

    The issuance of share acquisition rights for 30,000 common shares to 1 external collaborator has been additionally specified as an incentive measure to promote medium- to long-term corporate value enhancement.
  8. FY2024-Q1AdvancedAnnual report

    「The payment procedures were completed on 6 December 2023. Class and number of shares to be issued 433,000 of the Company's common shares」

    The issuance and payment of 433,000 common shares to directors and audit & supervisory board members was completed under the restricted stock compensation plan. The measure aimed at medium- to long-term corporate value enhancement and value sharing with shareholders has been additionally specified.
  9. FY2023-Q2AdvancedAnnual report

    「At a meeting of the Board of Directors held on 8 February 2023, the Company resolved to issue stock acquisition rights as stock options to its employees and dispatched employees, as approved at the annual general meeting of shareholders held on 26 October 2022, with the aim of enhancing motivation and morale to contribute to the progress of the Company's research and development and thereby contributing to the enhancement of corporate value.」

    The issuance of stock options to employees and temporary staff has been additionally specified as an incentive measure to promote medium- to long-term corporate value enhancement.
  10. FY2023-Q1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 9 November 2022, the Company resolved to issue new shares under its restricted stock compensation plan as set out below, and the payment procedures were completed on 7 December 2022.」

    The issuance and payment of 280,000 common shares to directors and audit & supervisory board members was completed under the restricted stock compensation plan.
  11. FY2022RestatedAnnual report

    「The current compensation structure is based on fixed compensation, with a restricted stock compensation plan and a stock option plan introduced as long-term incentives for directors and audit & supervisory board members. The Company has not introduced performance-linked compensation that varies with short-term results.」

    The policy of promoting medium- to long-term corporate value enhancement through a combination of fixed compensation, restricted stock and stock options, without introducing short-term performance-linked compensation, has been reaffirmed.
  12. FY2022-Q3AdvancedAnnual report

    「Eleventh Series of Share Acquisition Rights (A) Classification and number of eligible recipients (people) Company employees 33 Number of share acquisition rights (units)* 3,576 Class, details and number of shares underlying the share acquisition rights (shares)* Common shares 357,600 (Note) 1」

    As a specific medium- to long-term incentive measure, share acquisition rights for 357,600 shares were granted to 33 employees.
  13. FY2022-Q1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 11 November 2021, the Company resolved to issue new shares under its restricted stock compensation plan as set out below, and the payment procedures were completed on 10 December 2021.」

    The issuance and payment of 81,000 restricted shares to directors and audit & supervisory board members was completed under the existing medium- to long-term incentive policy.
  14. FY2021ReframedAnnual report

    「The current compensation structure is based on fixed compensation, with a restricted stock compensation plan and a stock option plan introduced as long-term incentives for directors and audit & supervisory board members. The Company has not introduced performance-linked compensation that varies with short-term results.」

    The explanation based on fixed compensation and stock options has been expanded to include a restricted stock compensation plan, broadening the composition of medium- to long-term incentives.
  15. FY2020First statedAnnual report

    「The Company determines the compensation structure for its officers primarily with a view to sustained enhancement of corporate value over the medium to long term and shareholder returns. The current compensation structure is based on fixed compensation, with stock options introduced as a long-term incentive for directors and audit & supervisory board members. The Company has not introduced performance-linked compensation that varies with short-term results.」

    In light of the business's long research and development and monetization cycle, the Company has for the first time explicitly stated its policy of basing compensation on fixed pay, providing long-term incentives through stock options, and not introducing short-term performance-linked compensation.
Moved together

"Increasing incentives to contribute to R&D and auditing through stock options" moved the same way as this thread, in the same document, in 15 of its 22 moves.

1599865★123456
  1. ★This thread
  2. 1Increasing incentives to contribute to R&D and auditing through stock options15×
  3. 2Clinical development of HMGB1 peptides for multiple indications9×
  4. 3Strengthening the financial base through funding from capital markets and investors9×
  5. 4Initiating clinical trials for osteoarthritis of the knee, cardiomyopathy and cirrhosis8×
  6. 5Capital reduction to preserve flexibility and agility in capital policy6×
  7. 6Applying for approval of an epidermolysis bullosa treatment following the Phase II trial5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for StemRIM yet. It last moved in the General Meetings of Shareholders of 2026-10-06: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.